Participants 115 156 4
venous thromboembolism in cancer patients
Participants 377 523 4
This study is a prospective assessment of anti-Xa levels in patients on long-term therapy for acute venous thromboembolism who have active cancer.
Participants 524 774 4
Consecutive consenting patients from one center in a multicenter trial that compared 6 months of low molecular weight heparin with oral anticoagulant therapy were treated with therapeutic doses of dalteparin (200 IU per kilogram) subcutaneously daily
Participants 948 1019 3
There were 24 patients who had anti-Xa levels measured at weeks 1 and 4
